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1. Introduction 
Carbohydrates have rarely been a matter of research by medicinal chemistry-oriented 
scientists in the past, but has recently gained substantially more publicity [1]. Although 
equally or even more abundant in nature than peptides/proteins or nucleic acids, they were 
often simply neglected as potential drug targets and/or drug leads or even drug candidates. 
There are a number of reasons for this. Glycans – complex carbohydrates linked to proteins 
or lipids are essential components of every cell surface as all cells are coated with a so-called 
glycocalyx layer. These cell surface carbohydrates allow for intercellular communication by 
binding to the carbohydrate-binding proteins (CBPs). Many physiological and even 
pathophysiological processes like pathogen-cell contact rely upon these interactions. 
Currently, more than 80 human CBPs have been identified [2,3], so one might immediately 
recognise CBPs as promising targets for anti-infective therapy. However, only a few of them 
have been thoroughly studied and as a result, few CBPs have been recognised and validated 
as drug targets. Furthermore, CBPs’ affinity is generally weak per monosaccharide unit, so 
CBPs usually form strong interactions by binding massive glycans that bear several hundred 
terminal carbohydrate units, many of which form contact with a single CBP or even a cluster 
of CBPs on the cellular surface. To inhibit glycan-protein interaction efficiently, one would 
have to consider designing and synthesizing multivalent carbohydrate ligands. This is by no 
means an easy task, and makes CBPs relatively unattractive targets in terms of druggability. 
Even if one would consider producing multivalent carbohydrates with optimal 
pharmacodynamic properties, they possess unattractive pharmacokinetic properties. 
Carbohydrates, especially large multivalent ones, share some intrinsic pharmacokinetic 
shortcomings as drugs; they are rapidly digested in the gut in most cases, and even if they 
survive the gut metabolism obstacles, they are practically unable to passively diffuse 
through the enterocyte layer in the small intestine. This inevitably means that no oral 
application can be guaranteed for a carbohydrate drug, which is the preferred application 
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route. Once in the body, carbohydrates are mostly a source of energy, but are also excreted 
rapidly with glomerular filtration. Due to these drawbacks, carbohydrates or carbohydrate-
derived drugs were often considered unappealing even before their design would take 
place. 
To tackle the first drawback, advances in CBP biochemistry has led to a progressive gain of 
knowledge on CBPs. A vast international research network named Consortium for Functional 
Glycomics (CFG, http://www.functionalglycomics.org/static/consortium/consortium.shtml) 
was founded in 2001 with the ultimate goal of enlightening the role of glycans and glycan-
binding proteins. To date, hundreds of members of this network as well as outside 
researchers have revealed the secrets of CBPs and many are now considered potential drug 
targets: their specific ligands were discovered with screening on large glycoarrays and their 
binding sites were mostly elucidated [3]. Understanding the 3D structures of CBPs and their 
binding modes is indispensable for drug design. In order to offer a central repository of 
knowledge available about CBPs, PROCARB has been constructed [4]. PROCARB is a 
database of known and modelled carbohydrate-binding protein structures with sequence-
based prediction tools, and is a single resource where all the relevant information about a 
pair of interacting proteins and carbohydrates is available. A similar, although a bit less 
appealing and informative database on lectin 3D structure is the database of lectins of Centre 
de Recherches sur les Macromolécules Végétales (CERMAV), a French fundamental research 
centre devoted to glycosciences (http://www.cermav.cnrs.fr/lectines/). Glycoscience.de 
(http://www.glycosciences.de/) is a German internet portal to support glycomics and 
glycobiology research. These web sites offer proof that the scientific community has 
recognised the potential of CBPs. Accordingly, many national and international associations 
have been involved in deciphering CBPs fundamental roles in human pathophysiological 
processes, which inevitably leads to on-going cognizance of how CBPs might be exploited to 
help develop novel therapeutic approaches for treatment of human diseases. 
CBPs may be classified primarily into two broad categories: lectins (which are further 
subdivided into specific types, like C-, H-, I-, L-, P-, R-, and S-type lectins) and sulphated 
glycosaminoglycan-binding proteins [3]. Extracellular lectins are the most promising drug 
targets among CBPs and CFG divides them into 4 specific groups: C-type lectins, galectins 
(or S-type lectins), siglecs (a subclass of I-type lectins that bind sialic acid) and other. Out of 
174 total CBPs records on the CFG webpage, 120 of them are classified as C-type lectins, 
which in itself highlights the importance of this class of CBPs. Like all extracellular lectins, 
C-type lectins bind terminal carbohydrate epitopes of glycans that originate from either 
pathogens or other cells. DC-SIGN, (Dendritic Cell-Specific Intercellular adhesion molecule-
3-Grabbing Non-integrin) is a type II C-type lectin that functions as an adhesion molecule 
located exclusively on dendritic cells (DCs). Originally discovered in 1992 [5], it was defined 
as a C-type lectin capable of binding the HIV-1 envelope glycoprotein gp120, but it took 
time until Steinman [6] and van Kooyk [7] unravelled its specific role in immunology and 
pathology and revealed the information to the broader scientific community. Since then, it 
has been shown to have a major role in primary immune response [8], but it also enhances 
several pathogens (like HIV, Ebola) infection of T cells and other cells of the immune system 
 
DC-SIGN Antagonists – A Paradigm of C-Type Lectin Binding Inhibition 139 
[7,9]. This makes DC-SIGN a very interesting CBP and a target of interest towards novel 
immunomodulatory and anti-infective therapy. DC-SIGN function can be modulated by 
small molecules termed DC-SIGN antagonists that bind to DC-SIGN and prevent binding of 
native DC-SIGN ligands. These molecules could act as novel anti-infectives, and are 
currently in the early phase of drug development. Latest in vitro studies demonstrate that 
DC-SIGN antagonists effectively block the transmission of pathogens like HIV-1 and Ebola 
to CD4+ T cells [10]. Although DC-SIGN has not been validated in vivo as a drug target yet, 
DC-SIGN antagonists are a fruitful example of how inhibition of a C-type lectin function 
might be achieved by small synthetic molecules. As exposed before, CBPs’ affinity is 
generally weak per carbohydrate unit, so the design of molecules that bind to DC-SIGN 
with high affinity is a demanding assignment. In general, the affinity issue and 
pharmacokinetic drawbacks of carbohydrates may be overcome by two predominant 
strategies implied in the design of DC-SIGN antagonists: screening of non-carbohydrate 
compounds to obtain ligands that are completely devoid of carbohydrate nature [11] and the 
design of glycomimetics, the compounds designed based on carbohydrate leads which 
usually still retain some or even a significant degree of carbohydrate nature [3,12]. DC-SIGN 
binds mannose- and fucose-based oligo- and polysaccharides, so their glycomimetics have 
been designed and proved to inhibit pathogen-DC-SIGN interaction potently. The author 
foresees that the approach used to design glycomimetic DC-SIGN antagonists is of general 
applicability when designing lectin antagonists and will be the thoroughly presented in the 
present chapter.  
2.1. C-type lectins 
Probably the largest type or family of lectins is the C-type found on animal (and human) 
cells [13]. This family includes several endocytic receptors and proteoglycans, and all 
collectins and selectins identified to date. They are of paramount importance for normal 
function of the immune system, as they mediate innate immunity, inflammation and 
immunity to tumour and virally infected cells. Although these CBPs vary greatly in 
structure among themselves, they have in common a domain, named C-type lectin-like 
domain (CTLD) or carbohydrate recognition domain (CRD). It is a compact globular 
structure responsible for selective binding of terminal units found in large carbohydrates 
[14]. The unique structural hallmark of such a domain is that it binds a carbohydrate by Ca2+ 
ion, which acts as a bridge between the protein and the “core monosaccharide” unit through 
complex interactions with sugar hydroxyl groups [15]. Namely, the binding with Ca2+ ion 
involves just one terminal saccharide unit – the “core monosaccharide” (as illustrated in 
Figure 1 for two distinct C-type lectins, the mannose-binding protein and DC-SIGN), while 
other ligand carbohydrate units (if present) form structural and bonding complementarity 
with the CRD. Several amino acid residues of the CRD offer 6 coordinate bonds for a Ca2+ 
ion and the carbohydrate donates 2 coordinate bonds with its hydroxyls, so that the Ca2+ ion 
is octacoordinated [16]. Distinct CRD aminoacid residues form hydrogen bonds with other 
hydroxyl groups on the carbohydrate directly or through water bridges. Changes in the 
amino acid residues that interact with the “core monosaccharide” modify the carbohydrate-
binding specificity of the lectin, so that specific carbohydrate is recognised. 
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Figure 1. Binding mode of 2 C-type lectin CRDs with the “core monosaccharide”. a) Crystal structure of 
mannose-binding protein with N-acetylgalactosamine (GalNAc) in the binding site (PDB code: 1AFB) 
[17]. b) Crystal structure of DC-SIGN in complex with Man4 tetrasaccharide (PDB code: 1SL4) [18]. The 
3- and 4-OH groups of the “core monosaccharide” (sticks rendering, without hydrogens) directly 
coordinate Ca2+ (blue sphere) and form hydrogen bonds with amino acids that also serve as Ca2+ 
ligands. Ca2+ is octacoordinated (violet broken line). For the sake of clarity, proteins are presented as 
transparent surfaces with amino acid residues (thin sticks) that coordinate Ca2+. 
The free energy of such interactions is relatively weak per carbohydrate unit, as we have to 
take into account high desolvatation penalties of numerous hydroxyls upon carbohydrate 
binding. The C-type lectin family however has means to obtain high binding affinity, or 
better, avidity; some C-type lectins oligomerize in order to promote high avidity for specific 
glycans [19]. The clustering of the CRDs influences not only avidity, but also the lectin 
selectivity, since each individual CRD can act independently to bind end mono- or 
oligosaccharide moiety [20]. Although the majority of lectins contain a single C-type CRD, 
the macrophage mannose receptor has multiple independent CRDs in a single polypeptide. 
The adjacent CRDs in the mannose receptor may help to direct its binding to specific 
multivalent, mannose-containing glycans [21]. 
2.2. DC-SIGN function and structure 
DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) 
is a C-type lectin that functions as an adhesion molecule expressed specifically by dendritic 
cells (DCs), a class of professional antigen presenting cells (APCs). The intrinsic role of DCs 
is guidance of adaptive immune responses, since they are the major APCs that capture, 
process and present antigens [22]. DC-SIGN is a specific pattern recognition receptor (PRR) 
that recognizes distinct molecular patterns (PAMPs – Pathogen-Associated Molecular 
Patterns) of a number of pathogens [23]. It induces intracellular signalling pathways and 
triggers DC maturation upon pathogen binding [8,9]. To promote efficient transport of DCs 
towards effector cells – T cells, DC-SIGN binds human adhesion molecules ICAM-2 on 
vascular and lymphoid endothelium and enables cell interactions during DC migration [24]. 
Furthermore, DC-SIGN binding to ICAM-3 allows early antigen-nonspecific contact 
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between DC and T cells in the lymph nodes, enabling T cell receptor engagement by 
stabilizing the DC-T-cell interaction [25]. Thus, we may conclude that DC-SIGN enables 
some of the normal DC functions by binding endogenous ligands, but also modulates 
immune responses to diverse pathogens via its ability to induce antigen-specific 
intracellular signalling. 
DC-SIGN is a transmembrane C-type lectin that consists of one CRD, which defines the 
ligand specificity of the receptor, a neck region composed of seven complete and one 
incomplete tandem repeats, and a transmembrane region followed by a cytoplasmic tail 
containing recycling, internalization and intracellular signalling motifs (Figure 2) [9]. 
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Figure 2. DC-SIGN schematic structure: Ca2+ CRD responsible for ligand binding/selectivity, a neck 
region composed of seven complete and one incomplete repeats, and a transmembrane region followed 
by a cytoplasmic tail (modified from Švajger et al.) [9]. 
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Like many other C-type lectins, DC-SIGN tetramerizes to increase binding affinity and 
oligomerization occurs through association of the DC-SIGN neck domain (Figure 3) [26]. 
The oligomerization status of the DC-SIGN and related C-type lectins depends on the 
number of helical repeats of the neck region; at least 6 repeats are needed for tetramerization 
[27]. The stacked CRDs of tetramerized DC-SIGN provides the means of increasing the 
specificity for multiple repeating (oligo)saccharide units on host molecules, thereby defining 
the set of pathogens or endogenous molecules that are recognized by DC-SIGN. DC-SIGN 
neck domain, while allowing stacking and tetramerization, plays a central role as a pH-
sensor that balances the equilibrium between the monomeric and tetrameric states of DC-
SIGN [28]. In this sense, affinity for carbohydrates may be changed markedly by changing 
the pH, which helps DC-SIGN to realize its native function. Namely, upon binding, 
pathogen particles are internalized and further degraded into smaller particles and 
conjugated to MHC class-II proteins. As degradation proceeds in an acidic endosomal 
environment, the acid-triggered pathogen release from DC-SIGN is needed for successful 
degradation. Apart from tetramerization, DC-SIGN forms clusters that organize in 
membrane microdomains [29]. This organization on the plasma membrane is important for 
the binding and internalization, suggesting that clustered assemblies act as functional 
docking sites for pathogens (Figure 3). 
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Figure 3. Tetramerization of DC-SIGN and further clustering allows high binding avidity and 
influences pathogen binding, as depicted with the example of HIV-1 binding to DCs: tetramerization 
increases avidity to PAMPs like gp120 on HIV-1 surface, while DC-SIGN clusters act as functional 
docking site for HIV-1 (modified from Švajger et al.) [9]. 
Apart from allowing oligomerization, DC-SIGN neck repeat domains separate CRDs from 
the cell surface to enable multivalent interaction with glycans. DC-SIGN binds particularly 
well to viral and bacterial glycans with closely spaced terminal oligo- or monosaccharides 
with roughly 5 nm between the units [18,30,31]. DC-SIGN is not a totally rigid 
macromolecule and shows a degree of flexibility upon ligand binding [31]. Namely, DC-
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SIGN adapts to an arrangement of terminal oligo- and monosaccharides, so all CDRs are 
allowed to interact with their ligands. Taken together, the tetrameric form of DC-SIGN and 
its conformational flexibility enable effective and selective binding of various glycans. 
Furthermore, due to the nature of the receptor-mediated cellular signalling, tetramerization 
of DC-SIGN could contribute to signal transduction after ligand binding. 
2.3. DC-SIGN, a target for anti-infective therapy 
Probably the most important feature of DC-SIGN is its ability to bind a great number of 
highly virulent pathogens [32]. Accordingly, it has been recognised as a potential new target 
for anti-infective therapy that perpetuates basic research of considerable importance. Apart 
from the already mentioned CFG, the importance of DC-SIGN as a new drug target is 
reflected in several other projects aimed to thoroughly clarify its function in pathogen 
infection. For example, several prominent European research teams have joined to form 
CARMUSYS, a collaborative training project aimed at designing and synthesizing 
carbohydrate multivalent systems to be used as inhibitors for pathogen attachment and 
penetration into target cells (CARMUSYS - Carbohydrate Multivalent System as Tools to Study 
Pathogen Interactions with DC-SIGN). 
DC-SIGN modulates the outcome of the immune response of DCs by binding and 
recognizing a variety of microorganisms, including viruses (HIV-1, HCV, CMV, Dengue, 
Ebola, SARS-CoV, HSV, coronaviruses, H5N1, West Nile virus, measles virus), bacteria (H. 
pylori, M. tuberculosis, L. interrogans), fungi (C. albicans, A. fumigatus) and parasites 
(Leishmania, S. mansoni) [9]. On mucosal surfaces of the body where immature dendritic 
cells sample pathogens, DC-SIGN serves as one of the very first pathogen attachment points 
and the usual result of this interaction is pathogen internalization, degradation and 
exposure of the pathogen PAMPs to recruit CD4+ T-cells and to start the humoral immune 
response [6,22]. HIV-1 exploits native DC-SIGN functions to enslave DCs as carriers to boost 
T cell infection with or without becoming infected themselves [33]. The very first interaction 
between HIV-1 and DCs occurs via HIV-1 envelope glycoprotein gp120 with DC-SIGN on 
immature DCs (Figure 3). The HIV-1-DC-SIGN complex is rapidly endocyted into early 
endosomes, where the acidic medium causes ligands to dissociate from DC-SIGN [34]. Upon 
dissociation, most DC-SIGN-bound ligands are lyzed and processed as a normal 
degradation pathway. Some HIV-1 particles however remain bound to DC-SIGN and thus 
protected from the host immune system, so a fraction of HIV-1 retains its infectiveness [35]. 
HIV-1 may rest in DCs in an infectious state for days, hidden in undefined bodies that differ 
from both endosomes and lysosomes [36]. N-glycan composition of surface proteins governs 
the viral faith upon interaction of viral envelope with DC-SIGN [37]. By altering the N-
linked glycan composition from mixed to oligomannose-enriched, one increases the affinity 
of HIV-1 for DC-SIGN, which enhances the viral degradation and reduces virus transfer to 
target cells. On the contrary, HIV-1 with oligomannose-enriched N-glycans is presented to 
viral envelope-specific CD4+ T cells more efficiently. In the alternative scenario, HIV-1 binds 
to DC-SIGN and facilitates lateral binding of HIV-1 to CD4 and CCR5 receptors expressed 
on the same immature DCs [33]. The direct consequence of this interaction is HIV-1 infection 
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of DCs [38]. To conclude, HIV-1 uses DC-SIGN as an entry mode to DCs, and DCs may be 
regarded as a Trojan horse that takes HIV-1 to CD4+ T-cells while protecting it from the host 
immune system [39]. A similar entry mode has been observed for some other pathogens like 
viruses (Ebola) and bacteria (M. tuberculosis, H. pylori) [32]. Apart from this straightforward 
infection pathway, HIV-1-infected DCs are able to mediate transmission of HIV-1 to CD4+ 
cells by means of immune response modulation and infectious synapse formation. Namely, 
HIV-1 causes both inhibition of DC maturation while inducing formation of viral synapse, a 
process previously attributed to mature DCs only [40]. As only several pathogens are able to 
modulate DCs maturation process, it may be concluded that the DC maturation depends 
upon selective ligand recognition, possibly also by DC-SIGN. 
The fact that DC-SIGN acts as an entry point and a mediator of pathogen infections points 
out the possible therapeutic usefulness of DC-SIGN. DC-SIGN antagonists work by 
inhibiting pathogen interaction with DC-SIGN, so the very first phase of pathogen infection 
can be inhibited, as proven in in vitro experiments [10,41,42]. DC-SIGN antagonists may be 
designed as monovalent glycomimetics based on the DC-SIGN-binding oligosaccharides 
and their multimeric presentation [43]. Alternatively, screening of compound libraries has 
been successful in obtaining non-carbohydrate DC-SIGN antagonists [44]. As mentioned, 
potential carbohydrate-derived drugs have poor pharmacokinetic properties in general and 
this might raise some concern as to whether there is potential for therapeutically useful 
glycomimetic DC-SIGN antagonists. In the case of HIV-1, the major initial contact site 
between HIV-1 and DC-SIGN is in the vaginal mucosa, so a DC-SIGN antagonist could be 
administered topically to prevent HIV-1 transmission without systemic application [45]. It 
has to be stressed that no clinically proven therapy based on inhibition of DC-SIGN-
mediated pathogen infection has been presented [43]. 
2.4. How does DC-SIGN choose among terminal monosaccharides? 
DC-SIGN has a highly regulated recognition of its ligands as it selectively binds glycans 
with terminal D-mannose- and L-fucose expressed on a number of bacteria, parasites, fungi 
and viruses [46]. However, the mere presence of D-mannose and L-fucose does not assure 
binding selectivity itself. Namely, monosaccharide binding to DC-SIGN CRD is generally 
very weak, with Ki(D-mannose) = 13.1 mM and Ki(L-fucose) = 6,7 mM being the strongest 
binders among monosaccharides [26]. DC-SIGN CRD forms a 1-to-1 complex with terminal 
mono- or oligosaccharides, which relies upon already mentioned octacoordination of Ca2+ 
ion in the binding site by the “core monosaccharide”; the equatorial 3- and 4-hydroxyls each 
form coordination bonds with the Ca2+ in the binding site common to all C-type lectins, but 
also offer hydrogen bonds with amino acids that also serve as Ca2+ ligands [47]. A crucial 
structural feature of a mannose residue is an axial position of the 2-hydroxyl group; this 
allows tight surface complementarity of the core mannose with the binding site. Equatorial 
position of the 2-hydroxyl group would probably prevent this tight binding due to steric 
clash, so hexopyranoses with equatorial 2-hydroxyl groups do not form strong interactions. 
To increase binding affinity, other saccharide units form additional interactions with the 
binding site, while binding specificity is based on spatial constraints. An excellent 
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description of selectivity/specificity mechanism may be found in the work of Guo et al., who 
demonstrated that DC-SIGN selectively binds high-mannose and fucosylated 
oligosaccharides [18]. The difference in the affinity of each oligosaccharide results from a 
different spatial arrangement of the mannose- and fucose-based ligands demonstrated in 
two crystal structures of fucose-based tetrasaccharide LNFP III and Man4 tetrasaccharide 
bound to DC-SIGN CRD; the Man3 mannose moiety of Man4 (the “core monosaccharide”) 
inclines the rest of the molecule towards Phe313 with high surface complementarity, while 
the fucose moiety (the “core monosaccharide” of LNFP III) makes hydrophobic contact with 
Val351 and positions the second saccharide in a vertical manner, away from the protein 
surface (Figure 4). The binding mode presented for Man4 tetrasaccharide (PDB code: 1SL4) 
in which Phe313 forms a steric hindrance is a prevalent one for a mannose-containing 
oligosaccharides. However several other PDB structures of DC-SIGN CRD (PDB code: 1K9I, 
1K9J, 2IT5 and 2IT6) show that Phe313 residue is rather flexible and allows 2 distinct 
binding modes, both including coordination of the Ca2+ by one mannose residue. One mode 
is shown in Figure 4, while in the second, the binding orientation of the mannose at the 
principal Ca2+ site is reversed, and creates different interactions between the terminal 
mannose and the region around Phe313 [47,48]. Thus we conclude that the binding mode of 
a specific oligosaccharide does not depend solely on the “core monosaccharide” involved, 
but is highly sensitive to the substitution pattern and 3D structure of adjacent 
monosacccharides. Furthermore, the mannose- and fucose-based ligands have overlapping, 
but different binding modes, which might offer a rational explanation for the different 
biological effects of mannose- and fucose-based ligands [49]. Consequently, the two 
observed binding modes offer a solid basis upon which DC-SIGN antagonists with either 
fucose or mannose anchors can be designed [50]. 
On the supramolecular level, DC-SIGN tetramerization has a major impact on binding 
affinity. By forming tetramers, binding affinity for glycans with repetitive sugar motifs with 
high-mannose or fucose N-linked oligosaccharides increases markedly [46]. This simple 
observation drives us to the conclusion that only polyvalent ligands could efficiently bind to 
DC-SIGN and offer a rationale for design of multivalent carbohydrate systems as DC-SIGN 
antagonists [51]. 
DC-SIGN was first regarded as the major binding lectin for various mannose-glycosylated 
PAMPS including HIV-1 gp120. However, other C-type lectins bind both D-mannose and L-
fucose-containing glycans, which brings under question DC-SIGN’s exclusive role in 
pathogen binding, but above all, raises the concern of binding selectivity when designing 
DC-SIGN antagonists. In particular, two C-type lectins - Langerin on epithelial Langerhans 
cells and a mannose receptor on dermal DCs - bind high-mannose oligosaccharides and 
HIV-1 gp120 with high affinity [52]. Their function in HIV-1 (and possibly other pathogen) 
infection differs: interaction of HIV-1 with DC-SIGN enables HIV-1 to survive a host 
immune system, while Langerin helps Langerhans cells to eradicate HIV-1 [53,54]. On the 
other hand, mannose receptor facilitates HIV-1 infection of DCs by the CD4/CCR5 entry 
pathway [53]. Therefore, blockade of both DC-SIGN and mannose receptors seems the right 
strategy for prevention of HIV-1 entry into DCs while Langerin inhibition suppresses viral  
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Figure 4. Selected amino acid residues (thin sticks) of DC-SIGN CRD (transparent surface) in complex 
with: a) Man4 tetrasaccharide (solid sticks, PDB code: 1SL4), and b) fucose-based tetrasaccharide LNFP 
III (solid sticks, PDB code: 1SL5) [18]. The Man3 mannose moiety of Man4 or the “core monosaccharide” 
inclines the rest of the molecule towards Phe313 with high surface complementarity, while the fucose 
moiety or the “core monosaccharide” of LNFP III makes hydrophobic contact with Val351 and positions 
the second saccharide in a vertical manner, away from the protein surface, so only one galactose moiety 
makes additional contacts with DC-SIGN CRD. 
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clearance thus allowing a boost of HIV-1 infection. When designing an efficient HIV-1 entry 
inhibitor based on C-type lectin antagonism, an agent of choice should bind to both DC-
SIGN and mannose receptors, while having no or marginal affinity to Langerin. Although 
all three receptors bind to virtually the same ligands, selectivity against Langerin is an 
achievable objective since Langerin binding sites differ from that of DC-SIGN [55]. As 
expected, selectivity versus Langerin does not necessarily rely on the “core 
monosaccharide” involved in the binding process, but on spatial constraints formed by 
adjacent glycan monosaccharide units [56]. 
2.5. Binding of monovalent DC-SIGN antagonists 
As mentioned earlier, binding of DC-SIGN natural ligands depends upon the presence of an 
L-fucose or D-mannose hexopyranose unit. Their inherent disadvantages in terms of low 
activity and/or insufficient drug-like properties can be modified by the design of 
glycomimetics – compounds that mimic the bioactive function of carbohydrates but have far 
better drug-like properties [3]. This concept has been successfully used in the design of 
monovalent DC-SIGN antagonists. The term “monovalent” is used here to describe low-
molecular weight molecules that can occupy only one DC-SIGN CRD at a time, so it 
incorporates mono- and oligosaccharide structures and their mimetics. The design of these 
monovalent glycomimetics can be structurally divided into the following sections, as 
depicted in figure 5: 
 the choice of a monosaccharide unit, 
 the choice of glycosidic bond surrogate, 
 the choice of adjacent saccharides or structures that contribute to overall binding 
affinity. 
 
Figure 5. Schematic presentation of the design of monovalent glycomimetics that act as DC-SIGN 
antagonists: systematic replacements in structure that lead to efficient DC-SIGN ligands. 
2.5.1. The choice of a monosaccharide unit 
The most extensive work regarding the choice of the monosaccharide unit comes from the 
work of Bernardi and Rojo’s groups from CARMUSYS [41,50,57]. In particular, they have 
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shown that L-fucose can be incorporated in glycomimetic surrogates of Lewis-X trisaccharide 
to obtain even better affinity than the native trisaccharide. The full Lewis-X mimetic 1 was 
shown to inhibit DC-SIGN binding of mannosylated BSA in the upper micromolar range 
(IC50=350 μM), but the second generation of analogous compounds failed to give any 
significant improvement over 1 (Figure 6) [50,58]. STD-NMR studies of 1 with DC-SIGN ECD 
have shown that only fucose residue makes strong contact with the DC-SIGN CRD. A 
reasonable explanation for this observation might be the before mentioned binding mode of 
the L-fucose moiety: it positions the second saccharide in a vertical manner away from the 
protein surface, and thus the rest of the molecule fails to form tight interactions with protein. 
Just a glance at figure 4 reveals that DC-SIGN CRD is quite flat and high structural 
complementarity is one of the requirements for strong binding. In the absence of functional 
groups that would allow ionic interactions which are not highly dependent on the distance, 
the rest of the Lewis-X mimetic 1 and its analogues probably form the majority of interactions 
with the solvent. Lewis-X mimetics however share one important figure; their affinity for 
Langerin is insignificant, so they are selective DC-SIGN antagonists [58]. 
The L-fucose monosaccharide has the highest affinity for DC-SIGN among 
monosaccharides, and L-fucose should be the logical choice as the “core monosaccharide” 
when designing DC-SIGN antagonists. On the contrary, D-mannose has received most of 
the attention as the majority of mono- and polyvalent DC-SIGN antagonists incorporate D-
mannose as the “core monosaccharide”. 
  
Figure 6. The choice of “core monosaccharide” of DC-SIGN antagonists; L-fucose (L-Fuc), D-mannose 
(D-Man), 2-substituted D-mannose and reduced shikimic acid are useful “core monosaccharides”. 
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Pseudo-1,2-mannobioside 2 and its analogues of Reina et al. (Figure 6) contain a D-mannose 
unit substituted at the anomeric position with conformationally constrained cyclohexanediol 
[41]. The STD-NMR of DC-SIGN ECD with an azido derivative of 2 shows that the 
compound makes close contact with the protein, which is in agreement with the binding 
mode of Man4 tetrasaccharide. The inhibitory activity of 2 on Ebola virus entry into DC-
SIGN expressing Jurkat cells was quite high (IC50=0.62 mM) and this was the first functional 
assay showing that DC-SIGN antagonism with small molecules might be used to inhibit 
viral transfection mediated by DC-SIGN. Another example of substituted D-mannose as the 
“core monosaccharide” might be found in the work of Mitchell et al.: they have synthesized 
a small library of 2-C-substituted branched D-mannose analogues of which compound 3 
exhibited a 48-fold stronger binding to DC-SIGN (Ki=0.35 mM, Ki(mannose)=17.1 mM) [59]. 
 
Figure 7. Design of reduced shikimic acid “core monosaccharide” as D-mannose mimetic [60]. 
An innovative approach was used by Garber et al.: taking D-mannose as the lead structure, 
they have concentrated on the spatial relationship of hydroxyls at positions 2,3 and 4 and 
concluded that reduced shikimic acid should enable the same spatial relationship of 
hydroxyls (Figure 7) [60]. They have synthesized 192 derivatives of reduced shikimic acid 
and compound 4 (Figure 6) was found to be the most potent hit of this focused library.  
2.5.2. The choice of glycosidic bond surrogate 
The metabolic instability of glycosidic bonds renders it inappropriate for the design of 
drugs, and hence requires an appropriate surrogate when designing mimetics of 
oligosaccharides. Numerous changes in carbohydrate structures have been successful in the 
design of glycosidase inhibitors, and exactly these structures could be used to modify 
glycosidic bond instability [61]. However, unwanted inhibition of glycosidases may as well 
provoke side effects of potential drugs, so careful choice of glycosidic bond surrogates has to 
be made if only its stability is the ultimate goal. The α-glycosidic bond found in both L-
fucose and D-mannose containing oligosaccharides that bind to DC-SIGN was successfully 
replaced by Timpano et al. by a stable α-fucosylamide structure (compound 1, Figure 6) and 
shown not to affect the binding affinity in a detrimental sense [50]. The derivatives of 
reduced shikimic acid (compound 4, Figure 6) have 2 features that influence glycosidic bond 
stability: first, they have a thioglycosidic bond, which is proven to be metabolically more 
stable towards glycosidases [62], and second, they are a constitute of reduced shikimic acid 
which is a carbasugar. Carbasugars lack anomeric reactivity, which implies their metabolic 
stability towards glycosidases and glycosyltransferases. Although glycosidic bond 
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surrogates were often not used in the design of DC-SIGN antagonists, the stability of 
glycosidic bonds has to be challenged when designing stable glycomimetics. According to 
the latest literature, a large number of alternatives already exist [63]. 
2.5.3. The choice of adjacent saccharides or structures that contribute to overall binding 
affinity 
Monosaccharide moieties other than “core monosaccharide” in the structure of DC-SIGN 
oligosaccharide ligands form not only additional interactions with the binding site, but also 
influence the binding specificity with spatial constraints and point other monosaccharide 
units towards or away from the protein surface, as seen in the Figure 4. Notable quality of 
the adjacent monosaccharide units is that they do not form the same interactions like the 
“core monosaccharide”, but instead form a network of H-bonds, possibly through water 
molecules. For example, Man4 tetrasaccharide makes contact with DC-SIGN through at least 
two water molecules, while one stabilizes its binding conformation [18,64]. Alternatively, 
both “core” and adjacent monosaccharides make surface complementarity and hydrophobic 
interactions. In particular, Van Liempt et al. demonstrated that Val351 in DC-SIGN creates a 
hydrophobic pocket that strongly interacts with the Fucalpha1,3/4-GlcNAc moiety of the 
Lewis antigens [65]. So, although highly polar in nature, the adjacent monosaccharide units 
contribute significantly to overall binding free energy also by hydrophobic interactions 
apart from being mere “linker” to other structures. This implies that altering hydrophilic 
character of adjacent monosaccharide units to more hydrophobic surrogates should increase 
free binding energy by increasing hydrophobic interactions. With this in mind, Timpano et 
al. have used the (1S,2R)-2-aminocyclohexanecarboxylic acid as a scaffold/linker to attach D-
galactose mimetic into the structure of compound 1 and its derivatives (Figure 8) [50]. The 
molecule was carefully chosen to mimic Lewis-X structure while minimizing the 
hydrophilic ballast of the Lewis-X, and galactose mimetic was incorporated based on the 
observation, that galactose residue makes contact with the DC-SIGN CRD surface and is 
thus important in binding [18]. 
 
Figure 8. (1S,2R)-2-aminocyclohexanecarboxylic acid as a scaffold/linker to attach D-galactose mimetic 
into the structure of compound 1 and its derivatives, all mimic Lewis-X [50]. 
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In the series of mannose-based DC-SIGN antagonists, Reina et al. and Sattin et al. (groups of 
Rojo and Bernardi) have incorporated (1S,2S,4S,5S)-dimethyl 4,5-dihydroxycyclohexane-1,2-
dicarboxylate as adjacent monosaccharide mimicking “trans” conformation of 1,2-hydroxyls 
in D-mannose (Figure 9, compounds 2 and 5) [10,41]. Again, the rational for this change was 
to imitate the 3D relationship of key hydroxyls in the D-mannose moiety, while lowering the 
overall hydrophilicity. Furthermore, the cyclohexane saccharide mimic lacks glycosidic 
bond and is thus metabolically stable. 
 
Figure 9. (1S,2S,4S,5S)-dimethyl 4,5-dihydroxycyclohexane-1,2-dicarboxylate as central 
monosaccharide surrogate that mimics “trans” conformation of 1,2-hydroxyls in D-mannose. 
Starting from compound 2 or its azido derivative, the group of Bernardi (Obermajer et al.) 
continued to pursue the idea of increasing the binding affinity by identifying two binding 
areas around Phe313 in the DC-SIGN binding site that were only partially occupied by co-
crystallized tetramannoside Man4 [64]. These hydrophobic areas were targeted by attaching 
different hydrophobic moieties to deprotected carboxylates of pseudo-1,2-mannobioside 2 
(Figure 10). A number of mannose-based DC-SIGN antagonists were synthesized (an 
illustrative example is compound 6), and the majority of them inhibited DC adhesion at low 
micromolar concentrations improving the potency of the starting compound 2 by two orders 
of magnitude. Probably the same hydrophobic areas have contributed to the affinity of 4. 
 
Figure 10. Increasing potency of DC-SIGN antagonists by attaching hydrophobic moieties to 
deprotected carboxylates of 2 to afford 6 and its derivatives [64]. 
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2.6. Increasing affinity and/or avidity? 
The evident disadvantage of monovalent DC-SIGN antagonists – their low affinity for DC-SIGN 
and thus low potency – can be overcome by conjugating monovalent units to various scaffolds 
for polyvalent presentation (Figure 11) [51]. Namely, even the most potent monovalent ligands 
have inhibitory constants in low micromolar concentrations, while therapeutically useful 
compounds have the same effect in nanomolar or even picomolar concentrations. The 
polyvalent antagonists are believed to interact with possibly all DC-SIGN CRDs on tetramers, 
or perhaps, they might interact and collate DC-SIGN clusters on the cell surface in the same 
manner as HIV-1 increases its avidity to DC surface (depicted in Figure 3). The avidity observed 
for polyvalent ligands in general originates from multiple binding: the polyvalent molecule 
with reversible mechanism of binding has higher possibility for being bound to at least one of 
receptor binding sites (i.e. one of CRDs), so that dissociation rate constant significantly 
decreases [66]. The other rationale may be derived from the observation of Andrews et al., who 
concluded that the average loss of overall rotational and translational entropy accompanying 
drug-receptor interaction is a constant for relatively small molecules and was estimated to be 
approx. 14 kcal/mol at 310 K [67]. In other words, more favourable free binding energy is 
obtained by combining binding epitopes/structures into one larger molecule, and this is also 
true for uniting same monovalent structures into a large polyvalent one because all rotational 
and translational entropic losses that occur during binding of individual monovalent molecules 
are reduced to one entropic loss for a larger molecule. According to both theories, when larger 
polyvalent molecules are employed, binding avidity is observed instead of just a linear increase 
in binding affinity. The main concern when choosing appropriate polyvalent support is the 
spatial relationship between individual monovalent ligands: monovalent ligands should be 
appropriately spaced to allow binding to at least two binding sites (or CRDs in case of C-type 
lectins), otherwise avidity cannot be achieved. 
 
Figure 11. Strategy for increasing binding affinity/avidity of DC-SIGN antagonists: monosaccharides or 
monovalent glycomimetics are attached to polyvalent dendrimer or dendron core (modified from 
Anderluh et al.) [43]. 
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The first polyvalent DC-SIGN antagonists were designed, synthesized and assayed in the 
laboratories of Rojo and Delgado [68]. A simple glycodendritic core bearing 32 mannose 
residues conjugated to BoltornH30 dendrimer through a succinic acid spacer (7, Figure 12) 
hindered DC-SIGN mediated Ebola virus infection at nanomolar concentrations (IC50=337 
nM). In comparison, the same inhibition was achieved with only millimolar concentrations 
of α-methyl-D-mannopyranoside (IC50=1.27 mM); the core bears only 32 mannose residues 
and the difference in binding affinity is more than 3000-fold, which clearly indicates high 
binding avidity. 
 
Figure 12. Glycodendritic structure bearing 32 mannose residues conjugated to BoltornH30 dendrimer 
as DC-SIGN antagonist [68]. 
Relatively simple glycopolymers with a different load of combined α-mannose and β-
galactose in ratios were synthesized by Becer et al. and evaluated in inhibition of DC-SIGN-
gp120 binding (8, Figure 13) [69]. Glycopolymer with 25% mannose failed to inhibit gp120 
binding potently (IC50 of 1.45 μM), while glycopolymer with 100% mannose was far more 
efficient (IC50 of 37 nM) even when calculated per mannose unit, as it had approx. 40 times 
higher affinity compared with 4-times higher load of the mannose unit. 
Polyvalent DC-SIGN antagonists described before relied on the use of “core 
monosaccharide” only. The design and choice of a potent monovalent DC-SIGN ligand 
might reduce the requirement for huge dendrimeric presentation while retaining desired 
effect. Designed monovalent glycomimetic 4 (Figure 6) of Garber et al. was loaded onto a 
carefully selected multivalent core designed to link at least 2 CRDs of DC-SIGN tetramer as 
monovalent units were roughly 40Å apart, which is exactly the width of DC-SIGN CRD (8, 
Figure 13) [60]. Glycopolymer 8 with 29 units of 4 was found to have 1000-fold higher 
affinity for DC-SIGN (IC50=2.9 μM) than 4, showing that high avidity binding was obtained. 
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It is hard though to assess the relevance of designed monovalent ligand versus D-mannose, 
as the analogous polyvalent DC-SIGN antagonist bearing D-mannose or reduced shikimic 
acid was not synthesized. The direct evidence however came from the work of Sattin et al 
[10]. They have attached four copies of monovalent trimannoside mimetic 5 (Figure 9) to a 
tetravalent dendron 10 (Figure 14), which potently inhibited HIV-1 transfection to CD4+ T 
lymphocytes (>94 % inhibition at 100 μM). For comparison only, a tetrameric dendron 
bearing 4 copies of simple D-mannose (11, Figure 14) failed to inhibit HIV-1 transfection 
with even comparable potency (65 % inhibition at 100 μM). Furthermore, Dendron 10 
inhibited Ebola cis infection of Jurkat T cells one order of magnitude more potently than 
dendron 11 [70]. This data clearly demonstrates that potent monovalent DC-SIGN 
antagonists reduce the need for high polyvalency number and influences binding affinity 
markedly. 
 
Figure 13. Glycopolymers of Becer et al. and Garber et al. with high binding avidity [60,69].  
 
Figure 14. Tetravalent dendrons of Sattin et al. bearing four copies of monovalent trimannoside 
mimetic 5 (10) or D-mannose residue (11) [10]. 
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3. Conclusion; could it work for all C-type lectins? 
As mentioned earlier, all C-type lectins share a structural feature, namely C-type lectin-like 
domain (CTLD) or carbohydrate recognition domain (CRD) responsible for Ca2+-dependent 
selective binding of terminal mono- or oligosaccharide units of large carbohydrates. This 
implies that only the “core monosaccharide” makes contact with Ca2+ ion while other ligand 
carbohydrate units (if present) form structural and bonding complementarity with the CRD. 
From this point of view, the systematic approach presented herein could be of general 
applicability when designing glycomimetic C-type lectin antagonists. It consists of 
designing the monovalent ligand based on three distinct steps: the choice/design of a “core” 
monosaccharide unit, the choice/design of glycosidic bond surrogate and the choice/design 
of adjacent saccharides or structures that contribute to overall binding affinity. Still, the 
evident drawback of monovalent glycomimetics is their low affinity not only to DC-SIGN, 
but to lectins in general [3]. The other characteristic of C-type lectins is their ability to 
oligomerize, and further make clusters of functional oligomers. The tactics of polyvalent 
presentation targets exactly the oligomerized or even clustered structures and is a 
prerequisite of polyvalent structures as C-type lectin antagonists. Accordingly, high avidity 
for DC-SIGN and other C-type lectins can be achieved with high loading of monovalent 
ligands to various polyvalent systems. Taken together, the results of several groups 
presented in this chapter clearly demonstrate that this general procedure for designing 
glycomimetic DC-SIGN antagonists gives notable results, and according to the structural 
resemblance of diverse C-type lectin CRDs, there is a high probability of its applicability to 
distinct C-type lectins. 
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